Artzi’s team is interested in leveraging immune engineering to treat a range of diseases including cancer, autoimmune diseases, as well as for tissue engineering applications. To maximize therapeutic outcomes, her lab is studying how delivery regimen and administration mode of combination therapies synergize with clinically-available modalities, and is investigating their effect on therapy pharmacokinetics and pharmacodynamics. Her lab has engineered hydrogel-based systems that enable local and sustained delivery of therapeutics at the target size, as well as polymeric microneedle devices that afford transdermal drug delivery as well as sampling of skin interstitial fluid to facilitate noninvasive and temporal monitoring of biomarkers including cells and soluble factors. Artzi’s platform technologies find many applications that can help advance our understanding of disease mechanisms, enable repurposing drugs and deliver emerging drugs, while monitoring the responses to the therapy over time.